Table of Contents
TL;DR (1-minute read)
Six converging lines of evidence from Dr. Annelise Bocquet's documented 2025 threads are materialising in real time:
| Mechanism / Network | Evidence from Thread | 2026 Reality |
|---|---|---|
| Olfactory retrograde transport | BPL intranasal delivery + anatomical diagram | Full spike + nucleocapsid + M + E proteins sprayed directly onto nasal epithelium |
| Spike persistence & prion-like domains | Bocquet-Garçon (2024) + McKernan warnings | Same protein now delivered via new route under Taubenberger NIAID |
| Appointee conflicts | Monarez DARPA-DoD threads | Still influencing CDC/ARPA-H oversight |
| Ebola 2014 phylogeny cover | Lander + Kenema/Metabiota | Broad Institute ties resurfacing |
| Genomics hub & funding | Church/Lander + Epstein-adjacent + Moderna sequencing | mRNA legacy now feeding "universal" platform |
| GOF continuity | Taubenberger 2009 paper + H5N1 work | Acting NIAID Director + $500M HHS push |
The scientific answer is not "prove harm first" — it is halt until independent CNS biodistribution studies are published.
Executive Summary
Dr. Annelise Bocquet saw the chessboard in 2025.
She laid out the players, the funding streams, the papers, and the anatomical risk — not as conspiracy, but as pattern recognition from someone who actually reads the primary literature.
February 2026: every piece she placed is now moving exactly as mapped.
Jeffrey Taubenberger is Acting Director of NIAID. The same "Generation Gold Standard" intranasal platform (BPL-inactivated whole avian influenza viruses including H5N1) is being accelerated with $500 million in HHS funding. And the direct highway from your nose to your brain — the olfactory nerves piercing the cribriform plate — remains unstudied for full-length spike persistence in this new delivery method.
Video: The chessboard Dr. Bocquet mapped in 2025 — every piece now moving in 2026 policy. Source: @MeasslainteIRL, February 2026
Why this matters now
Nasal-spray delivery places antigens directly on the olfactory epithelium. Retrograde axonal transport can carry proteins into the olfactory bulb, entorhinal cortex, and hippocampus within hours. When those proteins include the same hydrophobic S2 fragments and unpaired cysteines that drive aberrant disulfide-linked aggregates, the risk profile changes from "mucosal immunity" to potential chronic neuroinflammation, ER stress, and proteotoxicity.
Dr. Bocquet's French-language precision and English recaps emphasised one thing above all: verify the papers yourself.
The Evidence Dr. Bocquet Documented — Now Playing Out
1. Appointee Conflicts: Susan Monarez at CDC/ARPA-H
Image: Susan Monarez at CDC/ARPA-H with documented DARPA-DoD conflicts. Source: @MeasslainteIRL Twitter threads, March-May 2025
It started with Susan Monarez at CDC/ARPA-H and her DARPA-DoD conflicts.
I called it out back in March–May 2025:
Full threads here:
2. Ebola 2014 Phylogeny Cover-Up
Image: Eric Lander's 2014 Ebola phylogeny paper (Gire et al., Science) framed Makona as purely natural while downplaying Kenema lab signals and Metabiota partnerships. Source: @MeasslainteIRL, February 2026
Then Eric Lander's 2014 Ebola phylogeny paper (Gire et al., Science, co-authored by Lander) that framed Makona as purely natural while downplaying Kenema lab signals and Metabiota partnerships.
Thread: https://t.co/dWkp6BwlQh
3. Genomics Hub: Church + Lander + Epstein + Moderna
Image: Ralph Baric (UNC Chapel Hill) + John Mascola NIAID collaboration on Nature spike-stabilization papers. Source: @MeasslainteIRL Twitter analysis
George Church (CRISPR godfather, Broad Institute) + Eric Lander = the genomics hub.
Epstein's name popped up… Broad Institute worked with Moderna on mRNA sequencing and variants. John Mascola (NIAID) was super tight with them on the spike-stabilization papers.
One of those Nature papers (2020) has Lander, Fauci, and Mascola all on it: https://t.co/k9mzpCtFiU
And another with Mascola + Ralph Baric: https://t.co/k9mzpCtFiU
4. The Full Web: Metabiota + Hunter Biden + DARPA + SARS-CoV-2
Image: The Epstein–Broad–Moderna–DARPA web. Connections between Metabiota, Hunter Biden, DARPA, and lab-origin signals for SARS-CoV-2. Graphic by @carl_jurassic. Source: @MeasslainteIRL
Then everything clicked: Metabiota + Hunter Biden + DARPA + lab-origin signals for SARS-CoV-2.
The Epstein–Broad–Moderna–DARPA web became impossible to ignore.
The threads Dr. Bocquet dropped:
5. The Part That Keeps Me Up At Night: Olfactory Nerve Anatomy
Image: Olfactory nerve anatomy. Your olfactory nerve goes right through the ethmoid bone (cribriform plate) into the brain. Source: Neuroanatomy literature, cited in @MeasslainteIRL analysis
The part that actually keeps me up at night is the science.
"New universal vaccine platform from HHS & NIH — whole inactivated viruses (BPL-1357 & BPL-24910).
Intranasal version already in human trials.
That means full spike + nucleocapsid + M + E proteins… sprayed straight up the nose.
Your olfactory nerve goes right through the ethmoid bone into the brain (see the diagram).
Dose of spike? Who knows.
I'm with Dr. McKernan on this — big NO."
6. The New Key Player: NIAID Leadership
Image: Official announcement of NIAID leadership changes. Source: NIAID/HHS
The same institutional networks that drove mRNA policy are now accelerating the intranasal platform.
Acting NIAID leadership continues pandemic virus research, including H5N1, coronaviruses, and gain-of-function studies.
The 2009 paper "The Persistent Legacy of the 1918 Influenza Virus" remains the foundational document for this work.
If you thought gain-of-function went away… it didn't.
The Patent Conflict: Creating the Problem and Profiting from the "Solution"
Dr. Jeffrey Taubenberger is named as an inventor on U.S. Patent 11,369,675 B2 for the BPL-inactivated bird flu vaccine platform—the same technology at the center of Trump's $500 million "Generation Gold Standard" program.
Patent title: "Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses."
The confirmed facts:
- NIAID Director: Taubenberger appointed Acting NIAID Director April 25, 2025
- Patent status: Named inventor on government-owned BPL vaccine patent
- Royalty allowance: Federal rules permit government inventors up to $150,000/year in royalties
- HHS funding: $500 million "Generation Gold Standard" program accelerates BPL platform
- Oversight role: Taubenberger directs NIAID while the platform he patented advances through trials
Source: Federal Register Notice, December 2019 - Patent confirmation; Science magazine, May 2025 - NIH patent confirmation and royalty disclosure.
The structural conflict:
- NIAID funds avian influenza virus research and gain-of-function studies
- Taubenberger, as NIAID Director, oversees this research portfolio
- Taubenberger holds patent rights to the vaccine platform for those same pathogens
- Personal financial stake in platform adoption via royalty structure
The data gap: No peer-reviewed studies quantify CNS biodistribution, olfactory bulb persistence, or neuroinflammation markers for intranasal BPL-1357 delivery. Phase 1 trials (45 adults, ~2025) focused on safety/immunogenicity, not long-term neurological outcomes.
NIAID-funded gain-of-function projects documented in public records:
- Hybrid H5N1 with human lung cell infectivity and antiviral resistance
- Chimeric avian influenza with enhanced replication traits
- H5N1 genes on vesicular stomatitis virus backbone (University of Pittsburgh)
- Bat–human hybrid influenza with mammalian adaptation (University of Missouri)
- Synthetic H5N1 reconstruction via reverse genetics (Kawaoka et al.)
The COVID-19 parallel: Classified DEFUSE proposal (EcoHealth Alliance/DARPA) outlined engineering SARS-like viruses with furin cleavage sites—methods now resurfacing in avian influenza research under similar institutional oversight.
Bocquet-Garçon (2024) & Complementary Mechanisms
Dr. Annelise Bocquet-Garçon's 2024 Cureus review remains the clearest mechanistic map: spike activates multiple PRRs (TLR2, TLR4, TLR7/8), NLRP3 inflammasome, NETosis, AXL-mediated efferocytosis failure, and IgG4 class switching.
None of these effects disappear when the same spike (plus nucleocapsid, M, E) is delivered intranasally in whole-virus form.
For detailed analysis of spike protein mechanisms, see Spike Protein Gain of Function: Why mRNA Injections Aren't Vaccines
The Burden of Proof Has Shifted
The platforms that were supposed to end pandemic fear were never identical to the ones now heading straight for the olfactory gateway. Manufacturing changes, delivery-route innovations, and unresolved network conflicts happened without arms-length safety validation.
What wasn't done:
- No CNS biodistribution studies for intranasal whole-virus delivery
- No olfactory nerve retrograde transport assessment
- No long-term neuroinflammation monitoring
- No independent replication of manufacturer safety claims
- No public disclosure of network conflicts
What was done instead:
- $500 million HHS acceleration
- Human trials already underway
- Same institutional networks in charge
- Regulatory reassurances without data
Key Takeaways
- Dr. Annelise Bocquet's 2025 mapping is validating in real time in 2026 policy.
- Intranasal BPL platforms place full structural antigens on a direct brain-access route.
- Spike's documented innate-immune effects do not vanish with the new delivery method.
- The same scientific and institutional networks drive both mRNA legacy and the new "universal" push.
- Regulatory reassurances continue to outpace transparent biodistribution data.
- The scientific response is not panic — it is rigorous, independent verification before rollout.
The Scientific Case for a Precautionary Halt
Until comprehensive CNS studies by researchers with no financial or institutional ties are published, the precautionary principle applies.
Specific studies needed before wider deployment:
- Olfactory nerve biodistribution: Quantitative tracking of intranasal antigens via retrograde axonal transport to olfactory bulb, entorhinal cortex, and hippocampus
- Protein persistence: Duration studies of full-length spike, nucleocapsid, M, and E proteins in neural tissue
- Neuroinflammation markers: Longitudinal assessment of microglial activation, astrocyte reactivity, and cytokine profiles
- Behavioral outcomes: Cognitive, olfactory, and motor function testing in animal models
- Dose-response curves: Threshold analysis for adverse neurological effects
- Independent verification: Studies by labs with no NIAID/HHS/moderna/pharma funding
Halt wider deployment. Demonstrate safety first.
Related Articles
- Spike Protein Gain of Function: Why mRNA Injections Aren't Vaccines
- Failed Resolution: Why mRNA Experiments Must Halt
- Pfizer Process 1 vs Process 2: Manufacturing Changes and Risks
- mRNA Vaccine DNA Contamination: SV40 Promoter & Integration Risks
Eyes open. Read the papers yourself.
This article is a direct scientific translation of Dr. Annelise Bocquet's February 2026 thread recap (posted via @MeasslainteIRL), cross-referenced with her 2025 analyses and the primary literature. Not medical advice.
Key Sources
- Dr. Annelise Bocquet-Garçon. Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review. Cureus 2024. PMID: 38549864
- Taubenberger JK. The Persistent Legacy of the 1918 Influenza Virus. J Infect Dis 2009.
- Gire SK et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014.
- NIAID. BPL-1357 & BPL-24910 Intranasal Influenza Vaccine Platform (official announcements)
Date: March 24, 2026 Classification: INTRANASAL VACCINE SAFETY - POLICY ANALYSIS
